Research on NI-FAPI-04 for the Treatment of Hypoxic and Fibroblast Activation Protein Related Tumors
Exploratory Study of a Novel Dual Target Molecular Probe NI-FAPI-04 for Intra Irradiation Therapy of Hypoxic and Fibroblast Activation Protein Related Tumors
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
Beijing Municipality
-
Beijing, Beijing Municipality, China
- Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age between 18-80 years old
- Obtain pathological results through surgery or biopsy
- Loss of surgical opportunity (distant metastasis, or unsuitability for surgery due to contraindications); The condition still progresses after conventional chemotherapy, radiotherapy, targeted drug therapy, and other treatments (according to RECIST/PERCAST criteria)
- Expected survival time greater than 6 months
- Baseline [68Ga] Ga-NI-FAPI-04 PET/CT imaging reveals high uptake lesions
- Informed consent and the ability to accept follow-up
- Bone marrow reserve: neutrophil count ≥ 1.5 × 109/L; platelet count ≥ 100 × 109/L; hemoglobin ≥ 90 g/L
- Liver function: AST/ALT ≤ 3 × ULN, or subjects with liver metastasis<5 × ULN; Albumin>3.0 g/dL; Total bilirubin ≤ 1.5 × ULN
- Renal function: creatinine clearance rate ≥ 50 mL/min
- Coagulation function: INR ≤ 1.5 (for patients who have not received warfarin treatment); Prothrombin time (PTT)<2 × ULN
Exclusion Criteria:
- Pregnant and lactating female patients
- Individuals who fear confinement or radiation
- Individuals who have received systemic anti-tumor treatment, including chemotherapy or curative radiotherapy, within 4 weeks prior to their first medication, or who have received TKI treatment within 2 weeks
- Patients treated with isotopes such as strontium-89, samarium-153, rhenium 186, rhenium 188, radium-223, etc. within 6 months
- Individuals who have experienced severe allergic reactions to the components of [177Lu] Lu-NI-FAPI-04 injection in the past
- Received any investigational medication within 28 days prior to the first dose, or participated in another clinical study at the same time (except for those who participated in observational, non interventional clinical studies, or are currently in the follow-up period of interventional clinical studies)
- Patients who are difficult to receive further diagnosis and treatment due to severe illness
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: NI-FAPI group
Injection of [177Lu]Lu-NI-FAPI
|
Subjects were injected with 177Lu-NI-FAPI at 60mCi or 120mCi.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of participants with treatment-related adverse events as assessed by CTCAE v5.0
Time Frame: 6-8 weeks after administration
|
According to CTCAE v5.0, the number of patients who experienced adverse events was counted
|
6-8 weeks after administration
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Visual analysis of PET images before and after treatment
Time Frame: 6-8 weeks after administration
|
Describe the location of the lesion
|
6-8 weeks after administration
|
|
The size of the lesion before and after treatment
Time Frame: 6-8 weeks after administration
|
Measure the size of the lesion(cm)
|
6-8 weeks after administration
|
|
The degree of uptake of the lesion before and after treatment
Time Frame: 6-8 weeks after administration
|
Semi-quantitative analysis of changes in lesion uptake (SUVmax) before and after treatment
|
6-8 weeks after administration
|
Other Outcome Measures
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Objective response rate of [177Lu] Lu-NI-FAPI-04
Time Frame: 6-8 weeks after administration
|
Compare [68Ga] Ga-NI-FAPI-04 PET/CT and [18F] FDG PET/CT with baseline PET imaging after standardized dose treatment, and count the number of patients with objective responses and calculate the objective response rate
|
6-8 weeks after administration
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- I-25PJ0466
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.